Join Our Expert-Led Discussion on Optimising Hidradenitis Suppurativa Care: Personalised Treatment Approaches and Advanced Therapeutic Strategies with Insights from Australasian Guidelines with Professor John Frew.
Early diagnosis and disease awareness
Question 1: What challenges do clinicians face when diagnosing HS, and how does the modified Dessau Criteria aid in differentiating HS from similar conditions?
Question 2: How do the modified Hurley staging and the International Hidradenitis Suppurativa Severity Score System (IHS4) contribute to a more accurate assessment of HS severity, and why are they preferred over previous measures like the original Hurley staging and the Sartorius score?
Management of HS
Question 3: What factors should guide the initial treatment choice for mild to moderate HS, and how do individual patient factors like gender, medications, and allergies affect decisions?
Question 4: How do antibiotics, oral contraceptives, and spironolactone aid in managing mild to moderate HS, and what are their benefits and limitations?
Management of HS during pregnancy and flare management
Question 5: How can clinicians plan and manage HS flares effectively, considering variability in definitions and impacts on quality of life, and address repeated flares indicating therapy resistance?
Question 6: What factors should be considered when deciding to continue monoclonal antibody therapies during pregnancy for moderate to severe HS, balancing maternal and fetal health risks and benefits?